Announcements

** Therapeutic Vaccine Conference, New York, February 11-12

About a dozen leading AIDS vaccine researchers will gather
on February 11-12 for The 2nd Annual Forum on HIV Vaccine and
Immune Therapies, cosponsored by the Gay Men's Health Crisis
(GMHC) and the Community Research Initiative on AIDS (CRIA).
Scheduled speakers include Robert Redfield, M. D., Fred
Valentine, M. D., Allan Goldstein, Ph.D., Ronald Desrosiers,
Ph.D., Martha Eibl, M. D., and Bernadine Healy, M. D.

The conference will be at The Marriott Marquis Hotel,
Westside Ballroom, 45th and Broadway, New York City.

For more information, call CRIA, 212/924-3934.

** Liposomal Daunorubicin for Advanced KS: Limited Expanded
Access Program

Liposomal daunorubicin, a treatment which may be a
significant advance over other chemotherapy for treatment of
Kaposi's sarcoma, is currently in phase III clinical trials, and
will also be offered without charge to patients with advanced KS
who are not eligible for the trials and who have failed other
chemotherapy, through designated physicians in New York, Los
Angeles, and San Francisco, and possibly also in Miami and
Chicago. This program is limited because of short supplies of
the drug.

Conventional daunorubicin is approved for treating leukemia,
but has severe toxicities and can damage the heart and other
organs. In the liposomal form of the drug, the daunorubicin is
trapped in microscopic spheres composed of certain fats. In this
form, the drug is selectively absorbed by the abnormal cells in
the KS lesions, allowing high doses to be used with little
toxicity. According to information released by Vestar, of 75
patients with advanced KS who had failed conventional therapy, 60
percent improved on liposomal daunorubicin, and most of the rest
remained stable; fewer than five percent of the patients got
worse.

Liposomal daunorubicin (brand name DaunoXome() is also being
tested as a treatment for certain solid-tumor cancers not related
to HIV.

The developer, Vestar, Inc., of San Dimas, California,
worked with ACT UP/Golden Gate in San Francisco, and with ACT
UP/New York, in setting up this program. Andy Zysman, M. D., of
ACT UP/Golden Gate commented: "It has been very gratifying for
us to be able to work so cooperatively with a company to achieve
our common goal: namely, for patients to gain access to a new
drug as soon as its efficacy has been demonstrated in clinical
trials. Vestar's role in this process has been a model for the
industry, and we're looking forward to weaving a close
partnership among physicians, patients, and the company. The
limited drug supply remains a problem, and we hope that the
company can expand the program as the need becomes evident."

For more information, contact the DaunoXome Study Center,
800/247-3303.

** Sarasota Clinic Seeks Medical Director

The Comprehensive Care Clinic, Inc., in Sarasota, Florida,
is seeking a medical director. Full-time responsibilities
include medical examinations, clinical drug trials, and ARNP
supervision. Internal medicine, family practice, or infectious
disease specialist preferred. Send resume to: Comprehensive Care
Clinic, 150 East Ave. So., Sarasota, FL 34237, phone 813/366-
0461.